Research at CRE REDUCE aims to:
- Describe the effect of different infection pathologies on plasma & infection site antibiotic pharmacokinetics
- Define doses for patients that prevent the development of resistance
- Test patient tolerability & capacity to suppress the emergence of antibiotic resistance of novel doses in clinical trials & measure cost-effectiveness
- Trials to measure the effect of PK/PD interventions on clinical outcomes
- Improve the patient experience for novel treatment of infections through consumer participation in CRE research
- Support development of new antibiotic dosing guidelines for treatment of difficult infections through publication through Australian & international societies